Keyphrases
Multidrug-resistant
100%
Cancer Cell Lines
100%
Acute Leukemia
100%
Leukemia Cell Lines
100%
Histone Deacetylase Inhibitor (HDACi)
100%
AN-9
100%
Primary Leukemia Cells
100%
Primary Cancer Cells
100%
Selective Toxicity
100%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
30%
Hematological Malignancies
20%
IC50
20%
HL-60 Cells
20%
Chemoresistance
20%
Acute Lymphoblastic Leukemia Cells
20%
Working Diagnosis
20%
Cytotoxicity
10%
Induced Apoptosis
10%
Anticancer Agents
10%
Butyrate
10%
Granulocytes
10%
IC50 Value
10%
Colony Formation Assay
10%
Doxorubicin
10%
Monocytes
10%
Hematopoietic Stem Cells
10%
Antiproliferative Activity
10%
Primary T Cells
10%
Erythroid
10%
Acute Myeloid Leukemia
10%
Selective Agents
10%
Colony Forming Units
10%
Conventional Chemotherapy
10%
B-precursor ALL
10%
Prodrug
10%
Butyric Acid
10%
MDR1 Gene
10%
Solid Malignancies
10%
50% Inhibitory Concentration
10%
Infant Leukemia
10%
Doxorubicin-resistant
10%
Am(III)
10%
Resistant Clones
10%
Medicine and Dentistry
Acute Leukemia
100%
Leukemia Cell Line
100%
Cancer Cell Line
100%
Histone Deacetylase Inhibitor
100%
IC50
100%
Acute Lymphoblastic Leukemia
75%
Hematopoietic System Malignancy
50%
Malignant Neoplasm
50%
HL60
50%
Doxorubicin
50%
Drug Resistance
50%
Precursor
25%
In Vitro
25%
Anticarcinogen
25%
Programmed Cell Death
25%
Granulocyte
25%
Cancer
25%
Monocyte
25%
Genetic Transfection
25%
Acute Myeloid Leukemia
25%
Leukemia Cell
25%
Antiproliferative Activity
25%
Butyric Acid
25%
Pivaloyloxymethyl Butyrate
25%
P21
25%
Burst Forming Unit E
25%
Leukemia
25%
Cytotoxicity
25%
Colony Forming Unit S
25%
Prodrug
25%
Pharmacology, Toxicology and Pharmaceutical Science
Leukemia
100%
Malignant Neoplasm
100%
Acute Leukemia
100%
Histone Deacetylase Inhibitor
100%
IC50
100%
Acute Lymphoblastic Leukemia
75%
Doxorubicin
50%
Hematopoietic System Malignancy
50%
Drug Resistance
50%
Cytotoxicity
25%
Chemotherapy
25%
Butyrate
25%
Prodrug
25%
Anticarcinogen
25%
Pivaloyloxymethyl Butyrate
25%
Acute Myeloid Leukemia
25%